Additive manufacturing, commonly known as 3D printing, has emerged as a revolutionary technology within the biopharmaceutical industry, offering considerable benefits. One of the most compelling advantages of additive manufacturing is its potential to optimize cleanroom space through the
PureTech Health, a Boston-based biotechnology firm, employs an innovative "hub-and-spoke" model, centralizing resources and expertise to support various offshoot companies focused on specific therapeutic areas or drug-making technologies. This approach aims to merge the strengths of a centralized
In a surprising move to address ongoing financial difficulties and strategic challenges, CVS Health has made a significant leadership change by replacing CEO Karen Lynch with David Joyner, head of Caremark. This transition underscores the pressing need for CVS to stabilize its operations and refine
In a bold move that underscores its commitment to advancing cancer therapies, Novartis has taken a significant step by investing $70 million upfront in Chengdu Baiyu Pharmaceutical for global rights to a small molecule cancer treatment. This partnership is accompanied by potential milestone
Quantum BioPharma Ltd. (NASDAQ: QNTM) is making strategic moves to enhance its presence in the health and wellness sector through its subsidiary, Celly Nutrition Corp. Celly Nutrition has clinched a Master Distribution Agreement with FUSION Consulting Group for its innovative product, Unbuzzd.
Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes
Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and
The pharmaceutical industry is on the cusp of transformative changes over the next decade. Driven by new legislation and technological advancements, companies are rethinking traditional practices. The Biosecure Act, soon to be enacted in the US, and the rise of AI and automation, are key drivers of
The realm of biotechnology and digital health is increasingly characterized by burgeoning partnerships between pharmaceutical giants and innovative start-ups. These alliances are more than just trendy business moves; they represent a technological and strategic pivot aimed at advancing research,
The Biosecure Act, proposed by the U.S. government last year, aims to safeguard national security by regulating how genetic and biological data are handled, specifically targeting entities linked to adversarial governments like China. With a focus on preventing U.S. federal agencies from engaging
